相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atazanavir A Review of its Use in the Management of HIV-1 Infection
Katherine F. Croom et al.
DRUGS (2009)
Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the multicenter AIDS cohort study
Sharon A. Riddler et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
Miguel Goicoechea et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Toxicities Associated with Dual Nucleoside Reverse-Transcriptase Inhibitor Regimens in HIV-Infected Children
Russell B. Van Dyke et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study:: a multi-cohort collaboration
Caroline A. Sabin et al.
LANCET (2008)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Jean-Michel Molina et al.
LANCET (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
J. J. Kiser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir
Nicola Gianotti et al.
AIDS (2007)
Oxidant stress and peripheral neuropathy during antiretroviral therapy: An AIDS Clinical Trials Group Study
Todd Hulgan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions
AE Zimmermann et al.
CLINICAL INFECTIOUS DISEASES (2006)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe:: Implications for clinical management
AMJ Wensing et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
M Johnson et al.
AIDS (2005)
Prevalence of Antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy
RM Novak et al.
CLINICAL INFECTIOUS DISEASES (2005)
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
RK Zeldin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities
HS Weinstock et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
A review of low-dose ritonavir in protease inhibitor combination therapy
CL Cooper et al.
CLINICAL INFECTIOUS DISEASES (2003)
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee et al.
NUCLEIC ACIDS RESEARCH (2003)
Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors
UA Walker et al.
AIDS (2002)
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia
A Carr et al.
LANCET (2001)
分享论文
